Group One Trading, L.P. Arcus Biosciences, Inc. Transaction History
Group One Trading, L.P.
- $3.01 Billion
- Q2 2024
A detailed history of Group One Trading, L.P. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 23,769 shares of RCUS stock, worth $421,899. This represents 0.01% of its overall portfolio holdings.
Number of Shares
23,769
Previous 74,840
68.24%
Holding current value
$421,899
Previous $1.41 Million
74.36%
% of portfolio
0.01%
Previous 0.05%
Shares
12 transactions
Others Institutions Holding RCUS
# of Institutions
203Shares Held
48.9MCall Options Held
173KPut Options Held
151K-
Black Rock Inc. New York, NY9.76MShares$173 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.26MShares$93.3 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA4.25MShares$75.4 Million0.65% of portfolio
-
State Street Corp Boston, MA3.06MShares$54.2 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.83MShares$32.6 Million0.08% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.28B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...